Ernexa Therapeutics Inc. (ERNA) earnings date, results and what the price requires
Nasdaq · SEC CIK 0000748592 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | — | $-4.0M | $-3.40 | Filing |
| Mar 31, 2026 | May 11, 2026 | — | $-5.5M | $-6.95 | Filing |
| Dec 31, 2025 | Mar 13, 2026 | — | $-1.5M | $70.86 | Filing |
| Sep 30, 2025 | Nov 7, 2025 | — | $-1.2M | $-0.15 | Filing |
| Jun 30, 2025 | Aug 13, 2025 | — | $-3.1M | $-15.19 | Filing |
| Mar 31, 2025 | May 7, 2025 | — | $-8.2M | $-57.76 | Filing |
| Dec 31, 2024 | Mar 12, 2025 | $1,000 | $-5.8M | $41.31 | Filing |
| Sep 30, 2024 | Nov 12, 2024 | $487,000 | $-26.6M | $-73.70 | Filing |
What would Ernexa Therapeutics Inc. have to report for its valuation to change?
At $2.09, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -68.8% a year, to $0.18. On that path the next quarter needs diluted EPS near $-0.05, against $-0.15 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -68.8% | -68.8% |
| EPS needed in final year | $0.18 | $0.18 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. ERNA goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.